Bristol-Myers Squibb Company vs Dell Technologies Inc.: Strategic Comparison

This in-depth comparison examines Bristol-Myers Squibb Company and Dell Technologies Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Dell Technologies Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Dell Technologies Inc. is widest.

On the headline numbers, Bristol-Myers Squibb Company reports annual revenue of $48.2B against $113.5B for Dell Technologies Inc., while their respective market capitalizations stand at $127.5B and $360.0B. Both Bristol-Myers Squibb Company and Dell Technologies Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Dell Technologies Inc.: Dell Technologies is one of the largest IT hardware companies in the world and, by 2026, one of the leading OEM suppliers of AI servers. It sells the laptops and desktops used by most large corporations and the servers, storage and networking that run their data centers. Founded by Michael Dell in 1984, taken private in 2013, combined with EMC in 2016 and relisted in 2018, it is now a fast-growing AI infrastructure company with a market value of roughly $360 billion in late September 2026.

Bristol-Myers Squibb Company and Dell Technologies Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Dell Technologies Inc..

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

Dell Technologies Inc. business model: Dell makes money by selling hardware plus attached services and financing. The Infrastructure Solutions Group sells AI-optimized servers built around Nvidia (and some AMD) accelerators, traditional PowerEdge servers, networking and storage to enterprises, cloud service providers and governments; in Q2 fiscal 2027 ISG produced $31.8 billion of revenue and $4.8 billion of operating income. The Client Solutions Group sells commercial and consumer PCs, workstations and displays; Q2 fiscal 2027 CSG revenue was $15.0 billion, 88% of it commercial. Dell sells directly through its own sales force and dell.com and through channel partners, and adds recurring revenue from ProSupport warranties, deployment services, APEX subscriptions and Dell Financial Services leasing. AI servers carry thinner margins than storage or traditional servers, so Dell's profit growth depends on volume, configure-to-order supply chain efficiency and attaching higher-margin storage, networking and services.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Dell Technologies Inc..

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Dell Technologies Inc. competitive advantage: Dell's edge is breadth and scale in enterprise relationships. It can sell a customer everything from 10,000 laptops to a liquid-cooled GPU cluster with storage, networking, deployment and financing under one contract, and support it worldwide. Its configure-to-order supply chain, purchasing power with Nvidia, Intel, AMD and memory suppliers, and the 'Dell AI Factory with NVIDIA' reference designs let it ship large AI racks quickly; Dell said it had more than 4,000 AI customers by early 2026. Long-standing ownership of the commercial PC installed base also gives it a natural channel to sell AI PCs and infrastructure to the same IT buyers.

Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Dell Technologies Inc. each plan to expand from here.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

Dell Technologies Inc. growth strategy: Dell's growth strategy has three parts. First, win AI infrastructure share by shipping GPU-dense, liquid-cooled rack systems (PowerEdge XE servers with Nvidia Blackwell-generation GPUs) to neoclouds, sovereign AI programs and large enterprises, packaged as the Dell AI Factory. Second, attach higher-margin storage (PowerScale, PowerStore, Dell's private-cloud and data-lakehouse software), networking and services to those deals. Third, capture the commercial PC refresh with the simplified Dell, Dell Pro and Dell Pro Max brands introduced in 2025 and AI PCs. Capital returns through dividends and buybacks remain part of the equity story.

A closer look at the financial trajectory of Bristol-Myers Squibb Company and Dell Technologies Inc. rounds out the comparison.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.

Dell Technologies Inc.: Dell's fiscal year ends in late January or early February. Revenue fell from $102.3 billion in fiscal 2023 to $88.4 billion in fiscal 2024 as post-pandemic PC demand faded, then recovered to $95.6 billion in fiscal 2025 and a record $113.5 billion in fiscal 2026, when net income reached $5.94 billion, operating cash flow topped $11 billion and $7.5 billion was returned to shareholders. Fiscal 2027 has accelerated: Q1 revenue was $43.8 billion (up 88%) and Q2 revenue was $47.0 billion (up 58%), with Q2 diluted EPS of $6.34. In September 2026 Dell raised full-year fiscal 2027 guidance to about $192 billion in revenue and $25.50 in non-GAAP EPS. The balance sheet still carries debt from the 2016 EMC deal, though leverage has fallen through the VMware spin-off and cash generation.